on September 19, 2005
Published online before print September 19, 2005, doi: 10.1161/01.HYP.0000184541.24700.c7
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on July 5, 2005
From the Department of Preventive Medicine (S.N., G.L.B.), Hypertension/Clinical Research Center, Rush University Medical Center and Department of Medicine (C.J.P.), Division of Cardiovascular Medicine, University of Florida, College of Medicine, Gainsville, Fla. * To whom correspondence should be addressed. E-mail: gbakris{at}earthlink.net.
Abstract--Calcium antagonists comprise 2 main subclasses, dihydropyridines and nondihydropyridines, and have been studied extensively in hypertensive patients. Early meta-analyses suggested that short-acting calcium antagonists were associated with higher mortality rates resulting from cardiovascular events and other etiologies. Recent meta-analyses failed to show any substantive difference between long acting calcium antagonists and other antihypertensive drug classes with regard to cardiovascular outcomes in those with low to moderate cardiovascular risk or kidney disease progression among those with stage 2 or 3 nonproteinuric kidney diseases. The data from calcium antagonist trials are consistent in that they decrease stroke incidence but fail to protect against new-onset heart failure. In people with proteinuric kidney disease, that is >300 mg protein/gram creatinine, use of dihydropyridine calcium antagonists to lower blood pressure without the use of agents that block the renin angiotensin aldosterone system does not provide optimal slowing of nephropathy progression. This relates directly to lack of antiproteinuric effects with this subclass and not seen with nondihydropyridine agents that reduce proteinuria to a greater degree than dihydropyridines. Thus, calcium antagonists are safe and as efficacious as other antihypertensive agents to reduce cardiovascular risk. They should be avoided in people with systolic dysfunction but may be used for blood pressure lowering in people with preserved systolic function. Dihydropyridine calcium antagonists should only be used in conjunction with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in proteinuric kidney disease because they will not optimally slow kidney function loss in their absence.
Revised on August 3, 2005
Calcium Antagonists. Effects on Cardio-Renal Risk in Hypertensive Patients
Sandeep Nathan;
Key words: calcium antagonists • cardiovascular risk • hypertension • renal disease
This article has been cited by other articles:
 |
|
 |
|
  E. Perez-Reyes, A. L. Van Deusen, and I. Vitko Molecular Pharmacology of Human Cav3.2 T-Type Ca2+ Channels: Block by Antihypertensives, Antiarrhythmics, and Their Analogs J. Pharmacol. Exp. Ther., February 1, 2009; 328(2): 621 - 627. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A Kloner, J. Neutel, E. M Roth, R. Weiss, M. H Weinberger, K. M Thakker, B. Schwartz, H. Shi, A.-M. Gregg, and the ADHT Investigators Blood Pressure Control with Amlodipine Add-on Therapy in Patients with Hypertension and Diabetes: Results of the Amlodipine Diabetic Hypertension Efficacy Response Evaluation Trial Ann. Pharmacother., November 1, 2008; 42(11): 1552 - 1562. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Kobori, M. Nangaku, L. G. Navar, and A. Nishiyama The Intrarenal Renin-Angiotensin System: From Physiology to the Pathobiology of Hypertension and Kidney Disease Pharmacol. Rev., September 1, 2007; 59(3): 251 - 287. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Stults and R. E. Jones Management of Hypertension in Diabetes Diabetes Spectr, January 1, 2006; 19(1): 25 - 31. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Schachter Review: Blood pressure reduction in the metabolic syndrome and type 2 diabetes: current concepts The British Journal of Diabetes & Vascular Disease, November 1, 2005; 5(6): 320 - 324. [Abstract] [PDF]
|
|